• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by AVEO Pharmaceuticals Inc. (Amendment)

    11/1/22 5:01:48 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVEO alert in real time by email
    SC 13D/A 1 geoiv-aveo_18666.htm GROWTH EQUITY OPPORTUNITIES FUND IV, LLC -- SCHEDULE 13DAE (#6) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

     

     

    Aveo Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, $.001 par value

    (Title of Class of Securities)

    053588109

    (CUSIP Number)

    Louis S. Citron, Esq.

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    October 20, 2022

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 053588109

    13D Page 2 of 9 Pages    

    Schedule 13D

     

    Item 1.Security and Issuer.

     

    This Amendment No. 6 (“Amendment No. 6”) to Schedule 13D amends and restates the Schedule 13D originally filed on May 31, 2016, Amendment No. 1 thereto filed on April 4, 2017 (“Amendment No. 1”), Amendment No. 2 thereto filed on July 10, 2018 (“Amendment No. 2”), Amendment No. 3 thereto filed on November 28, 2018 (“Amendment No. 3”), Amendment No. 4 thereto filed on April 17, 2020 (“Amendment No. 4”) and Amendment No. 5 thereto filed on June 24, 2020 (“Amendment No. 5”) relating to the ordinary shares, $.001 par value (the “Common Stock”) of Aveo Pharmaceuticals, Inc. (the “Issuer”) having its principal executive office at 30 Winter Street, Boston, Massachusetts 02108.

     

    Certain terms used but not defined in this Amendment No. 6 have the meanings assigned thereto in the Schedule 13D (and Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5 thereto). Except as specifically provided herein, this Amendment No. 6 does not modify any of the information previously reported on the Schedule 13D (and Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5 thereto).

     

     

    Item 2.Identity and Background.

     

    This statement is being filed by:

     

    (a) Growth Equity Opportunities Fund IV, LLC (“GEO”);

     

    (b) New Enterprise Associates 15, L.P. (“NEA 15”), which is the sole member of GEO, NEA Partners 15, L.P. (“NEA Partners 15”), which is the sole general partner of NEA 15; and NEA 15 GP, LLC (“NEA 15 LLC” and, together with NEA Partners 15, the “Control Entities”), which is the sole general partner of NEA Partners 15; and

     

    (c) Forest Baskett (“Baskett”), Anthony A Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”), Joshua Makower (“Makower”), Scott D. Sandell (“Sandell”) and Peter W. Sonsini (“Sonsini”) (together, the “Managers”) and Peter J. Barris (“Barris”) and Joshua Makower (“Makower”). The Managers are the managers of NEA 15 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of GEO, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett, Makhzoumi, and Sonsini is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 Fifth Avenue, 19th Floor, New York, NY 10011.

     

    The principal business of GEO, and NEA 15 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 15 is to act as the sole general partner of NEA 15. The principal business of NEA 15 LLC is to act as the sole general partner of NEA Partners 15. The principal business of each of the Managers is to manage the Control Entities, GEO and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    GEO and NEA 15 LLC are limited liability companies organized under the laws of the State of Delaware. NEA 15 and NEA Partners 15 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

     

     

     

    CUSIP No. 053588109

    13D Page 3 of 9 Pages    

     

     

     

     

    Item 4.Purpose of Transaction.

     

    Not applicable.

     

     

    Item 5.Interest in Securities of the Issuer.

     

    Each of the Reporting Persons has ceased to own beneficially 5% or more of the Issuer’s Common Stock.

     

     

    Item 7.Material to be Filed as Exhibits.

     

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

     

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 053588109

    13D Page 4 of 9 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 1st day of November, 2022.

     

     

    GROWTH EQUITY OPPORTUNITIES FUND IV, LLC

     

    By:NEW ENTERPRISE ASSOCIATES 15, L.P.
    Sole Member

     

    By:NEA PARTNERS 15, L.P.

    General Partner

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                    *                               

    Louis S. Citron

    Chief Legal Officer

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:NEA PARTNERS 15, L.P.
    General Partner

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                    *                              

    Louis S. Citron

    Chief Legal Officer

     

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                    *                              

    Louis S. Citron

    Chief Legal Officer

     

     

    NEA 15 GP, LLC

     

    By:                    *                              

    Louis S. Citron

    Chief Legal Officer

     

     

     

     

     

     

    CUSIP No. 053588109

    13D Page 5 of 9 Pages    

     

     

     

     

                            *                              

    Forest Baskett

     

     

                            *                             

    Anthony A. Florence, Jr.

     

     

                            *                             

    Mohamad H. Makhzoumi

     

     

                            *                             

    Joshua Makower

     

     

                            *                             

    Scott D. Sandell

     

     

                            *                             

    Peter W. Sonsini

     

     

    */s/ Louis S. Citron                        

    Louis S. Citron

    As attorney-in-fact

     

     

    This Amendment No. 6 to Schedule 13D was executed by Louis S. Citron on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 053588109

    13D Page 6 of 9 Pages    

     

    EXHIBIT 1

     

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Aveo Pharmaceuticals, Inc.

     

    EXECUTED this 1st day of November, 2022.

     

     

     

    GROWTH EQUITY OPPORTUNITIES FUND IV, LLC

     

    By:NEW ENTERPRISE ASSOCIATES 15, L.P.
    Sole Member

     

    By:NEA PARTNERS 15, L.P.

    General Partner

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                    *                               

    Louis S. Citron

    Chief Legal Officer

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:NEA PARTNERS 15, L.P.
    General Partner

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                    *                              

    Louis S. Citron

    Chief Legal Officer

     

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                    *                              

    Louis S. Citron

    Chief Legal Officer

     

     

    NEA 15 GP, LLC

     

    By:                    *                              

    Louis S. Citron

    Chief Legal Officer

     

     

     

     

     

     

     

     

     

    CUSIP No. 053588109

    13D Page 7 of 9 Pages    

     

     

     

     

     

                            *                              

    Forest Baskett

     

     

                            *                             

    Anthony A. Florence, Jr.

     

     

                            *                             

    Mohamad H. Makhzoumi

     

     

                            *                             

    Joshua Makower

     

     

                            *                             

    Scott D. Sandell

     

     

                            *                             

    Peter W. Sonsini

     

     

     

    */s/ Louis S. Citron                        

    Louis S. Citron

    As attorney-in-fact

     

     

    This Agreement relating to Schedule 13D was executed by Louis S. Citron on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 053588109

    13D Page 8 of 9 Pages    

     

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

     

     

    /s/ M. James Barrett            

    M. James Barrett

     

    /s/ Peter J. Barris                

    Peter J. Barris

     

    /s/ Forest Baskett                

    Forest Baskett

     

    /s/ Ali Behbahani                 

    Ali Behbahani

     

    /s/ Colin Bryant                   

    Colin Bryant

     

    /s/ Carmen Chang               

    Carmen Chang

     

    /s/ Anthony A. Florence, Jr.

    Anthony A. Florence, Jr.

     

    /s/ Carol G. Gallagher          

    Carol G. Gallagher

     

    /s/ Dayna Grayson               

    Dayna Grayson

     

    /s/ Patrick J. Kerins             

    Patrick J. Kerins

     

    /s/ P. Justin Klein                

    P. Justin Klein

     

     

     

     

     

    CUSIP No. 053588109

    13D Page 9 of 9 Pages    

     

     

     

     

    /s/ Vanessa Larco               

    Vanessa Larco

     

    /s/ Joshua Makower             

    Joshua Makower

     

    /s/ Mohamad H. Makhzoumi

    Mohamad H. Makhzoumi

     

    /s/ Edward T. Mathers         

    Edward T. Mathers

     

    /s/ David M. Mott                

    David M. Mott

     

    /s/ Sara M. Nayeem            

    Sara M. Nayeem

     

    /s/ Jason R. Nunn                

    Jason R. Nunn

     

    /s/ Gregory Papadopoulos    

    Gregory Papadopoulos

     

    /s/ Chetan Puttagunta          

    Chetan Puttagunta

     

    /s/ Jon Sakoda                     

    Jon Sakoda

     

    /s/ Scott D. Sandell              

    Scott D. Sandell

     

    /s/ A. Brooke Seawell          

    A. Brooke Seawell

     

    /s/ Peter W. Sonsini             

    Peter W. Sonsini

     

    /s/ Melissa Taunton             

    Melissa Taunton

     

    /s/ Frank M. Torti                

    Frank M. Torti

     

    /s/ Ravi Viswanathan           

    Ravi Viswanathan

     

    /s/ Paul E. Walker               

    Paul E. Walker

     

    /s/ Rick Yang                      

    Rick Yang

     

      

    Get the next $AVEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVEO

    DatePrice TargetRatingAnalyst
    11/8/2022$15.00Buy → Hold
    Stifel
    7/12/2021$27.00 → $19.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AVEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

      The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston. The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors. The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI. Keynote speakers include: Steve Kraus, Partner at Bessemer Venture Partners and world-renown

      3/22/24 6:14:00 PM ET
      $BEAM
      $DASH
      $LYFT
      $AVEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Business Services
      Consumer Discretionary
    • LG Chem Completes Acquisition of AVEO Oncology

      SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology ("AVEO"), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, in an all-cash transaction with an implied equity value of $571M on a fully diluted basis. "We are excited to complete LG Chem's acquisition of AVEO, which will position us to deliver on our mission of becoming one of the world's leading oncology companies with a robust clinical pipeline of innovative therapies," said Shin Hak-Cheol, Chief Execu

      1/19/23 4:35:03 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Stockholders Approve Acquisition by LG Chem

      BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the "Special Meeting") held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. ("LG Chem"), a subsidiary of LG Chem and AVEO (the "merger agreement"). As previously announced, under the terms of the merger agreement, AVEO stockholders will receive $15.00 per share in cash upon the closing of the transaction. "Today's approval is a significant step toward the c

      1/5/23 7:35:35 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bate Kenneth returned $5,625 worth of shares to the company (375 units at $15.00), decreasing direct ownership by 50% to 375 units (tax liability)

      4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)

      1/19/23 5:19:11 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Evnin Anthony B returned $627,615 worth of shares to the company (41,841 units at $15.00), closing all direct ownership in the company to satisfy tax liability

      4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)

      1/19/23 5:16:18 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Ledell Jebediah (tax withholding)

      4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)

      1/19/23 5:16:10 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by AVEO Pharmaceuticals Inc. (Amendment)

      SC 13D/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)

      11/1/22 5:01:48 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AVEO Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)

      10/20/22 4:05:20 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AVEO Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)

      2/11/22 3:32:10 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    SEC Filings

    See more
    • SEC Form 15-12G filed by AVEO Pharmaceuticals Inc.

      15-12G - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)

      1/30/23 4:07:52 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by AVEO Pharmaceuticals Inc.

      EFFECT - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)

      1/24/23 12:15:15 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by AVEO Pharmaceuticals Inc.

      EFFECT - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)

      1/24/23 12:15:19 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FOTIVDA issued to AVEO PHARMACEUTICALS INC

      Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB HYDROCHLORIDE has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

      3/29/21 5:44:34 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FOTIVDA

      Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

      3/10/21 2:49:22 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AVEO Oncology downgraded by Stifel with a new price target

      Stifel downgraded AVEO Oncology from Buy to Hold and set a new price target of $15.00

      11/8/22 6:15:04 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on AVEO Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of AVEO Pharmaceuticals with a rating of Buy and set a new price target of $19.00 from $27.00 previously

      7/12/21 6:05:44 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on AVEO Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of AVEO Pharmaceuticals with a rating of Outperform and set a new price target of $18.00 from $10.00 previously

      3/11/21 6:30:25 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Leadership Updates

    Live Leadership Updates

    See more
    • AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer

      - Former chief operating officer of Enzyvant Therapeutics brings over 20 years of biotech leadership experience - AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the Company's organizational efficiency and advancing its pipeline of products. "We are excited to welcome Jeb to the team during an important phase of AVEO's evolution as an integrated clinical development and commercial organization," said Michael Bailey, president and chief executive officer of AVEO. "With a successful

      12/1/21 7:00:00 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors

      AVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company's Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director of the Program in Oncology at the University of Maryland School of Medicine. He also serves as director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. "Dr. Cullen, among the leading voices in cancer research and treatment, has made many important contributions to the evolving tre

      4/16/21 7:00:00 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update

      BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update. “The U.S. Food and Drug Administration’s (FDA) recent approval of FOTIVDA marks a transformative event for AVEO, and we are eager to demonstrate FOTIVDA’s potential to serve as a meaningful new treatment option within the growing relapsed or refractory advanced renal cell carcinoma (RCC) patient population. We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month,” said Michael Bailey, president and chief executive officer of AVEO. “In parallel, we remain focused on the evalua

      3/16/21 4:05:00 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Financials

    Live finance-specific insights

    See more
    • AVEO Oncology Reports Third Quarter 2022 Financial Results

      – Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Announced entering a definitive agreement under which LG Chem will acquire AVEO for $15.00 per share in an all-cash transaction with an implied equity value of $566 million on a fully diluted basis – BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights At September 30, 2022, AVEO r

      11/7/22 4:05:00 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash

      Acquisition Provides LG Chem's Life Sciences Division a Commercial Footprint in the U.S., Diversifies its Pipeline with a Broad Range of Oncology Therapies and Accelerates LG Chem's Efforts to Deliver Continued Growth AVEO Will Have Enhanced Ability to Deliver on its Mission to Improve the Lives of Patients with CancerAVEO to Establish and Operate as the U.S. Commercial Foundation for LG Chem Life Sciences' Oncology SegmentTransaction Price Represents a 43% Premium to AVEO's Closing Price on October 17, 2022 SEOUL, South Korea and CAMBRIDGE, Mass. and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) and AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercia

      10/18/22 4:30:00 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Reports Second Quarter 2022 Financial Results

      – Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1 2022 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100.0 million to $110.0 million – – Company Streamlines Planned R&D Spending and Lowers Guidance to $50.0 million from $60.0 million to $70.0 million – – Company to host conference call today at 4:30 p.m. ET – BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better

      8/4/22 4:05:00 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care